NGNima Ghadiri

Nima Ghadiri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nima Ghadiri has a total of 82 co-authors. Here are the top co-authors by number of shared publications:

  • Shi Zhuan Tan

    Department of Eye and Vision Science, Institute of Life Course and Medical Sciences, Faculty of Health & Life Sciences, University of Liverpool, William Henry Duncan Building, Liverpool, UK

    4 shared publications
  • Ian Pearce

    Royal Liverpool University Hospital, Liverpool, UK

    3 shared publications
  • Savita Madhusudhan

    St Paul’s Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom; Department of Eye and Vision Science, University of Liverpool, Liverpool, United Kingdom

    3 shared publications
  • Asterios Diafas

    Moorfields Eye Hospital, London, UK

    2 shared publications
  • Austin McCormick

    Liverpool University Hospitals NHS Foundation Trust

    2 shared publications
  • Ayodeji Ajanaku

    Liverpool University Hospitals NHS Foundation Trust

    2 shared publications

Latest Publications

  • Routine HIV testing in zoster eye disease

    by Ahmed Bakr, Navid Hakim, Paul Hine, Nardine Menassa, Nima Ghadiri

  • Open Access

    Dietary and lifestyle interventions in non-infectious uveitis: protocol for a systematic review

    by Shameer A Mohamed Naleer, Diya Shah, Julieta Lumanisakio, Desta Bokre, Nima Ghadiri, Harry Petrushkin, Alice Thomas

    Introduction Non-infectious uveitis (NIU) is a significant cause of visual impairment—often requiring long-term immunosuppressive therapy (which carries systemic side effects). There is growing interest in non-pharmacological adjuncts—broadly encompassing: dietary supplements, lifestyle modifications and psychological interventions—as an adjunct to treatment. However, the existing evidence is fragmented and lacks systematic synthesis. This is the first systematic review to identify and evaluate studies examining the relationship between modifiable lifestyle behaviours or dietary supplements and clinical outcomes in NIU, across both adult and paediatric populations. Methods A comprehensive literature search will be conducted across Ovid Medline, Ovid Embase, CENTRAL, CINAHL, Scopus, Web of Science and grey literature—with no date or language restrictions. Eligible studies will include randomised controlled trials and non-randomised controlled studies. Primary outcomes include flare frequency/severity, visual acuity, treatment response and adverse events. Secondary outcomes include health-related quality of life, inflammatory markers and mental health outcomes. Two reviewers will independently screen studies, extract data and assess risk of bias using Risk of Bias 2 and Risk of Bias in Non-randomised Studies of Interventions tools. Certainty of evidence will be evaluated using Grading of Recommendations, Assessment, Development and Evaluation (GRADE). A narrative synthesis will be conducted, with meta-analysis where appropriate, and heterogeneity assessed using I². Subgroup and sensitivity analyses will explore age, uveitis subtype, intervention type and study quality. Ethics and dissemination No ethical approval is required as this review synthesises publicly available data. Findings will be disseminated via peer-reviewed publication, professional conferences, patient advocacy organisations (eg, Uveitis UK). The protocol was prospectively registered with PROSPERO in August 2025 and follows Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) guidelines. PROSPERO registration number CRD420241077488.

  • Open Access

    Efficacy and Safety of Satralizumab for Thyroid Eye Disease: Week 24 Results from the Phase III SatraGO-1 and SatraGO-2 Randomized Trials

    by César A. Briceño, Oluwatobi O. Idowu, Jwu Jin Khong, Thomas Kuenzel, Ann Q. Tran, Christopher Brittain, Atsushi Azumi, Laura Brockwell, Nima Ghadiri, Mariano Coronel, et al.


  • Open Access

    Modernising patient education in vitreoretinal surgery

    by Jae Yee Ku, Rumana Hussain, Heinrich Heimann, Nima Ghadiri, Ivan Sychev, Max Griebsch, Aruni Makuloluwa, Christopher Ze Qian Go, Konstantinos Kaprinis, Tom Southern, et al.


  • Open Access

    Clearing the clouds: neural networks to forecast the aetiology of uveitis

    by Nima Ghadiri, Peter Thomas


  • Open Access

    The history of uveitis: from antiquity to the present day

    by Nima Ghadiri

    This comprehensive review traces the historical understanding and treatment of uveitis from ancient civilisations to modern medicine, a history which reflects the evolution of medical understanding and practice in general. Early descriptions of ocular inflammation appear in Egyptian medical papyri from 1700 BCE, with subsequent contributions from Greek and Roman physicians, including Hippocrates and Galen, who provided foundational observations of ocular inflammatory conditions. Medieval scholars in the Middle East, particularly Avicenna, preserved and advanced classical knowledge while recognising the systemic nature of ocular inflammation. The Renaissance and Enlightenment periods brought anatomical precision and the emergence of ophthalmology as a distinct specialty, notably through innovations such as Helmholtz’s ophthalmoscope in 1851. The twentieth century marked a paradigm shift with the evolution of immunological understanding, leading to the recognition of autoimmune mechanisms and genetic predispositions in uveitis. The introduction of corticosteroids mid-century revolutionised treatment, followed by the development of steroid-sparing immunomodulatory agents and, more recently, targeted biological therapies. Contemporary advances in imaging technology and the establishment of international collaborative groups have standardised classification and treatment approaches. This historical perspective demonstrates the progression from empirical observations to precision medicine in uveitis, highlighting the importance of understanding this evolution for advancing future therapeutic strategies.


  • Immune checkpoint inhibitors and the orbit; two cases of reactive dacryoadenitis

    by Matthew Fenech, Ayodeji Ajanaku, James Hsuan, Austin McCormick, Simon Shamas, Nima Ghadiri

    Immune checkpoints refer to mechanisms entrusted with the modulation of immune responses in peripheral tissues and are required for minimising collateral damage. Immune checkpoint inhibitors (ICPi) work through numerous pathways, including the anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), anti-PD-1 (programmed cell death protein 1) and the PD-L1 (protein cell death protein-ligand-1) pathways. They are proving to be an exciting therapeutic avenue in the attempt to activate anti-tumour activity. Ipilimumab is a fully human monoclonal antibody working on the anti-CTLA-4 pathway, while nivolumab and pembrolizumab are humanised monoclonal IgG4 antibodies that work on the PD-1 pathway. Despite a growing body of research pertinent to these novel therapies, early indications show that they are limited by their side effect profile. Furthermore, their efficacy appears to be greater in cancers with a high mutational burden. We present two female patients with bilateral reactive dacryoadenitis secondary to ICPi therapy, a finding that to the best of our knowledge was not previously described in the literature.


  • Orbital Kimura disease: maintenance therapy using mycophenolate mofetil

    by Matthew Fenech, Ayodeji Ajanaku, Austin McCormick, Sarah E. Coupland, Yamini Krishna, Ziyaad Sultan, Nima Ghadiri

    Kimura disease (KD) is a rare, chronic, inflammatory condition, predominantly found in male patients of Asian ethnicity. It typically presents between 50-60 years of age and usually with bilateral disease. Angiolymphoid hyperplasia with eosinophilia (ALHE) remains the main differential diagnosis, although histological analysis is essential in differentiating from other similarly presenting pathologies. In this case, we present an atypical case of unilateral orbital KD in a middle-aged, Caucasian, male gentleman and no evidence of regional lymphadenopathy along with a literature review of orbital KD and the differential diagnoses, histological features and management modalities available, adding to the sparse literature on the topic. At present, no recognised diagnostic criteria for KD are available, with histopathological analysis through incisional or excisional biopsy being the primary diagnostic method. Complete surgical excision with or without corticosteroid management remains the most common treatment modality although management is shifting to steroid-sparing immunomodulatory therapy. To the best of our knowledge, this is the first case to describe maintenance therapy of KD using mycophenolate mofetil.